Structural specificities of cell surface β-glucan polysaccharides determine commensal yeast mediated immuno-modulatory activities.
Animals
CD4-Positive T-Lymphocytes
Cell Differentiation
/ drug effects
Colitis
/ immunology
Cyclooxygenase 2
Dendritic Cells
/ immunology
Encephalomyelitis, Autoimmune, Experimental
Glucans
Homeodomain Proteins
/ genetics
Immunity
Immunomodulation
/ drug effects
Lectins, C-Type
Mannans
Mice
Mice, Inbred C57BL
Mice, Knockout
Polysaccharides
/ immunology
Saccharomyces cerevisiae
/ genetics
T-Lymphocytes, Regulatory
/ drug effects
Th1 Cells
Zymosan
beta-Glucans
/ immunology
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
14 06 2021
14 06 2021
Historique:
received:
04
06
2020
accepted:
24
05
2021
entrez:
15
6
2021
pubmed:
16
6
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Yeast is an integral part of mammalian microbiome, and like commensal bacteria, has the potential of being harnessed to influence immunity in clinical settings. However, functional specificities of yeast-derived immunoregulatory molecules remain elusive. Here we find that while under steady state, β-1,3-glucan-containing polysaccharides potentiate pro-inflammatory properties, a relatively less abundant class of cell surface polysaccharides, dubbed mannan/β-1,6-glucan-containing polysaccharides (MGCP), is capable of exerting potent anti-inflammatory effects to the immune system. MGCP, in contrast to previously identified microbial cell surface polysaccharides, through a Dectin1-Cox2 signaling axis in dendritic cells, facilitates regulatory T (Treg) cell induction from naïve T cells. Furthermore, through a TLR2-dependent mechanism, it restrains Th1 differentiation of effector T cells by suppressing IFN-γ expression. As a result, administration of MGCP display robust suppressive capacity towards experimental inflammatory disease models of colitis and experimental autoimmune encephalomyelitis (EAE) in mice, thereby highlighting its potential therapeutic utility against clinically relevant autoimmune diseases.
Identifiants
pubmed: 34127673
doi: 10.1038/s41467-021-23929-9
pii: 10.1038/s41467-021-23929-9
pmc: PMC8203763
doi:
Substances chimiques
Glucans
0
Homeodomain Proteins
0
Lectins, C-Type
0
Mannans
0
Polysaccharides
0
beta-Glucans
0
dectin 1
0
RAG-1 protein
128559-51-3
Zymosan
9010-72-4
Ptgs2 protein, mouse
EC 1.14.99.-
Cyclooxygenase 2
EC 1.14.99.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3611Références
Front Immunol. 2012 Sep 04;3:274
pubmed: 22969767
Carbohydr Polym. 2019 Aug 15;218:269-278
pubmed: 31221330
Appl Microbiol Biotechnol. 2015 Oct;99(19):7893-906
pubmed: 26252967
Clin Microbiol Rev. 2000 Oct;13(4):523-33
pubmed: 11023954
J Allergy Clin Immunol. 2016 Aug;138(2):558-567.e11
pubmed: 27177779
Vaccine. 2018 Aug 23;36(35):5226-5234
pubmed: 30057282
Annu Rev Immunol. 2015;33:257-90
pubmed: 25581309
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Nat Rev Immunol. 2010 Oct;10(10):735-44
pubmed: 20865020
Microbiol Spectr. 2017 May;5(3):
pubmed: 28513415
Int J Mol Sci. 2019 Jun 29;20(13):
pubmed: 31261851
Diabetes. 2015 Apr;64(4):1341-57
pubmed: 25377877
J Clin Invest. 2006 Apr;116(4):916-28
pubmed: 16543948
Cell Microbiol. 2008 Oct;10(10):2058-66
pubmed: 18549457
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Immunobiology. 2014 Oct;219(10):802-12
pubmed: 25092569
J Immunol. 1997 Jul 1;159(1):44-52
pubmed: 9200437
Nat Rev Immunol. 2011 Apr;11(4):275-88
pubmed: 21394104
Adv Immunol. 2010;108:111-65
pubmed: 21056730
Nat Immunol. 2019 Feb;20(2):218-231
pubmed: 30643268
Crit Rev Biotechnol. 2005 Oct-Dec;25(4):205-30
pubmed: 16419618
Front Immunol. 2018 Apr 16;9:673
pubmed: 29755450
Immunity. 1994 Oct;1(7):553-62
pubmed: 7600284
Nat Rev Immunol. 2015 Oct;15(10):630-42
pubmed: 26388329
Drug Discov Today Technol. 2020 Dec;35-36:57-68
pubmed: 33388128
Nat Med. 2017 Sep;23(9):1036-1045
pubmed: 28759052
Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:74-83
pubmed: 23201570
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Methods Enzymol. 2010;480:89-115
pubmed: 20816206
Nutr J. 2010 Nov 18;9:54
pubmed: 21087484
Nature. 1951 Jul 28;168(4265):167
pubmed: 14875032
ACS Omega. 2020 Jun 23;5(26):15973-15982
pubmed: 32656418
Exp Lung Res. 2013 Feb;39(1):48-57
pubmed: 23282019
Curr Opin Immunol. 2009 Feb;21(1):30-7
pubmed: 19223162
Nat Immunol. 2013 Jul;14(7):668-75
pubmed: 23778794
PLoS Comput Biol. 2021 Nov 8;17(11):e1009581
pubmed: 34748542
Sci Immunol. 2018 Oct 19;3(28):
pubmed: 30341145
J Inflamm (Lond). 2018 Mar 22;15:5
pubmed: 29588627
Anal Biochem. 2002 Feb 1;301(1):136-50
pubmed: 11811978
Cancer Cell Int. 2015 Nov 05;15:106
pubmed: 26549987
Nat Rev Immunol. 2017 Oct;17(10):635-646
pubmed: 28604735
J Exp Med. 1998 Mar 16;187(6):855-64
pubmed: 9500788
Immunity. 2010 May 28;32(5):681-91
pubmed: 20493731
J Exp Med. 2003 May 5;197(9):1107-17
pubmed: 12719479
Cancer Res. 2005 Jun 15;65(12):5211-20
pubmed: 15958566
J Immunotoxicol. 2008 Jan;5(1):47-57
pubmed: 18382858
J Immunol. 1992 Apr 1;148(7):2229-36
pubmed: 1347552
Nat Rev Immunol. 2014 Jun;14(6):405-16
pubmed: 24854590